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STAT3 activation is associatedwith poor prognosis in human colorectal cancer (CRC).Our previous data demonstrated that
regorafenib (Stivarga) is a pharmacological agonist of SH2 domain-containing phosphatase 1 (SHP-1) that enhances SHP-1
activity and induces apoptosis by targeting STAT3 signals in CRC. This study aimed to find a therapeutic drug that is
more effective than regorafenib for CRC treatment. Here, we showed that SC-43 was more effective than regorafenib at
inducing apoptosis in vitro and suppressing tumorigenesis in vivo. SC-43 significantly increased SHP-1 activity,
downregulated p-STAT3Tyr705 level, and induced apoptosis in CRC cells. An SHP-1 inhibitor or knockdown of SHP-1 by
siRNA both significantly rescued the SC-43–induced apoptosis and decreased p-STAT3Tyr705 level. Conversely, SHP-1
overexpression increased the effects of SC-43 on apoptosis and p-STAT3Tyr705 level. These data suggest that SC-43–
induced apoptosis mediated through the loss of p-STAT3Tyr705 was dependent on SHP-1 function. Importantly, SC-43–
enhanced SHP-1 activity was because of the docking potential of SC-43, which relieved the autoinhibited N-SH2 domain of
SHP-1 and inhibited p-STAT3Tyr705 signals. Importantly, we observed that a significant negative correlation existed between
SHP-1 and p-STAT3Tyr705expression in CRC patients (P = .038). Patients with strong SHP-1 and weak p-STAT3Tyr705
expression had significantly higher overall survival compared with patients with weak SHP-1 and strong p-STAT3Tyr705
expression (P= .029). In conclusion, SHP-1 is suitable to be a useful prognostic marker and a pharmacological target for
CRC treatment. Targeting SHP-1-STAT3 signaling by SC-43 may serve as a promising pharmacotherapy for CRC.
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Colorectal cancer (CRC) is a leading malignancy worldwide [1].
Regorafenib (BAY 73-4506, commercial name Stivarga) approved by
the Food and Drug Administration in September 2012 is a therapy
for the patients with metastatic CRC (mCRC) [2] and is a novel oral
multikinase inhibitor that targets the oncogenic receptor tyrosine
kinases as well as the RAF/MEK/ERK signaling pathway[3]. Based on
the clinical trial data, regorafenib significantly improves overall
survival (OS) of patients and serves as an effective and safe third-line
688 Targeting SHP-1-STAT3 Axis in CRC Fan et al. Neoplasia Vol. 17, No. 9, 2015pharmacotherapeutic option for mCRC patients with a KRAS
mutation, and is a third- or fourth-line option form CRC patients
with wild-type KRAS [2]. However, it is still necessary to improve OS
of CRC patients and provide an effective pharmacotherapeutic option
by searching for a novel anti-CRC therapy.
SH2 domain-containing phosphatase 1 (SHP-1) is a nonreceptor
protein tyrosine phosphatase (PTP) that was first identified in
hematopoietic cells and epithelial cells [4–6]. Notably, SHP-1 has
tumor-suppressive potential due to its negative regulation of STAT3
oncogenic signaling during tumor progression [7–10]. It contains two
SH2 domains, a catalytic PTP domain, and a C-terminal tail [10].
The tyrosine phosphatase activity of SHP-1 is highly dependent on its
structural variability. Most importantly, we demonstrate that SHP-1
is a druggable target of regorafenib in CRC [11]. Regorafenib induces
apoptosis of CRC cells in vitro and suppresses tumorigenesis in vivo
by relieving the autoinhibition of SHP-1 through the docking
potential of regorafenib into the N-SH2 domain of SHP-1 that
further downregulates p-STAT3Tyr705 level [11]. These observations
are also consistent with the recent findings that regorafenib exerts an
antitumor effect by targeting SHP-1–mediated STAT3 inhibition in
hepatocellular carcinoma (HCC) [12]. These results therefore
indicate that the pharmacological targeting of the SHP-1-STAT3
axis by regorafenib is a potential anticancer therapy.
Previously, our team discovered that the tyrosine phosphatase
SHP-1 plays a critical role in mediating a novel kinase-independent
antitumor effect of sorafenib [13]. Sorafenib treatment increases the
activity of SHP-1 tyrosine phosphatase in HCC cells by directly
disrupting the autoinhibited structure of SHP-1 between its N-SH2
and catalytic PTP domain [13]. Based on these findings, we further
generated a series of dimer-based derivatives of sorafenib that exert
antitumor effects via SHP-1 enhancing without kinase inhibition
properties, among which SC-43 is the most potent pharmacological
SHP-1 agonist [13]. In HCC cells, we found that SC-43 exerts better
in vitro and in vivo antitumor efficiency than sorafenib through
targeting SHP-1–dependent STAT3 inactivation in HCC preclinical
model [13]. In addition, preclinical tests also showed that SC-43 is a
highly active compound against breast cancer [14]. Notably, we also
found that regorafenib, a sorafenib analog developed by Bayer,
inhibits the survival of colon cancer cells through identical mode of
action on SHP-1 as sorafenib and SC-43 [11]. Because SC-43 has a
closely related chemical structure with regorafenib with depletion of
the kinase inhibition properties, a detailed preclinical testing on
SC-43 will help to address the feasibility of targeting SHP-1/STAT3
signaling for the treatment of CRC.
In this study, we discovered that SC-43 exerts more potent drug efficiency
than regorafenib and identified SC-43 as an SHP-1 agonist that activates
SHP-1–dependent STAT3 inhibition signaling in CRC. These findings
suggest that SHP-1 is a pharmacological target and prognostic marker of
CRC and also indicate that targeting the SHP-1-STAT3 axis with SC-43
may be a promising therapeutic approach to prevent CRC development.
Materials and Methods
Cell Culture
Colorectal cancer cell lines Hct-15, Hct-116, DLD1, HT-29, and
SW480 were maintained in RPMI 1640 medium supplemented with
10% fetal bovine serum and 100 U/ml of penicillin and streptomycin
(Invitrogen, Carlsbad, CA). Cells were then incubated at 37°C in a
humidified 5% CO2 atmosphere.Reagents and Plasmids
Regorafenib was kindly provided by Bayer Healthcare Pharma-
ceuticals. For in vitro studies, regorafenib and SC-43 were dissolved
in dimethyl sulfoxide and then added to the cells maintained in RPMI
1640 medium without FBS. For in vivo animal study, regorafenib
and SC-43 were suspended in Kolliphor (JT Baker). SHP-1 inhibitor
(PTPIII) was purchased from Calbiochem. Smart-pool siRNAs,
including control (D-001810-10) and SHP-1 (PTPN6, L-009778-
00-0005), were all purchased from Dharmacon (Chicago, IL).
Plasmids of human wild-type STAT3 and SHP-1 (PTPN6) were
encoded by pCMV6 vector with myc-tag. For mutant-type SHP-1
expression, we generated two plasmids, designated dN1 and D61A,
with a truncated N-SH2/PTP domain and aspartic acid at 61 changed
to an alanine residue, respectively. Both plasmids were cloned into
pCMV6 entry vector. These plasmids or siRNAs were subsequently
transfected into cells by using Lipofectamine 2000 Reagent
(Invitrogen, CA).
Cell Proliferation Assay
After treatment with regorafenib or SC-43 at the indicated doses
for 2 days, cell viability was measured using a 3-(4, 5-dimethylthia-
zol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. Cells were
counted and seeded in 96-well plates and then incubated at 37°C in a
humidified 5% CO2 atmosphere. Twenty microliters of MTT
reagent (5 mg/ml; Sigma, St. Louis, MO) was added to each well at
the end of incubation; 4 hours later, the medium was discarded, and
150 μl of dimethyl sulfoxide was added to each well to dissolve the
purple crystal. Then the absorbance at 540 nm was measured.
Experiments were performed three times in duplicate.
Sub-G1 Analysis
For the examination of cell population in the sub-G1 phase, both
floating and attached cells were collected and centrifuged before being
washed with cold phosphate-buffered saline, and then fixed in 70%
cold ethanol overnight at −20°C. Cells were incubated with 50 μg/ml
of propidium iodide and 20 μg/ml of Rnase A in the dark at
room temperature for 30 minutes and then analyzed by flow
cytometry (BD Biosciences, San Jose, CA).
Apoptosis Assay
Apoptotic cells were determined by using an enzyme-linked
immunosorbent assay (Cell Death Detection ELISAPLUS Kit; Roche
Molecular Biochemicals) according to the manufacturer's instruc-
tions. This apoptosis assay is used to measure DNA fragmentation
and histone release from the nucleus during the apoptosis process.
Briefly, CRC cells (1 × 105) were cultured in 96-well plate for 24
hours and then treated with dose escalation of regorafenib or SC-43
for 24 hours. After removing the supernatant from cells cultured in
96-well plate, 200 μl of lysis buffer per well was added and incubated
for 30 minutes at room temperature. Lysates were centrifuged, and
then 20 μl of supernatant was transferred into the streptavidin-coated
microplate. Eighty microliters of immunoreagent was added to each
well and incubated for 2 hours at room temperature. After each well
was rinsed with incubation buffer and 100 μl of ABTS solution was
added for 20 minutes, the absorbance at 405 nm was measured.
Western Blotting
Whole-cell lysates were resolved by sodium dodecyl sulfate
polyacrylamide gel electrophoresis. Proteins were transferred onto a
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incubated with the primary antibody, and then incubated with
horseradish peroxidase–conjugated secondary antibodies. Specific
proteins were detected using enhanced chemiluminescence reagent.
The primary antibodies used for Western blotting, including cyclin
D1 and PARP, were purchased from Santa Cruz Biotechnology (San
Diego, CA); p-STAT3, STAT3, Mcl-1 and survivin were purchased
from Cell Signaling (Danvers, MA); SHP-1 and β-actin were
purchased from Abcam (Cambridge, MA). For quantification of
protein levels on chemiluminescent Western blots, the densitometry
Image J software was employed.
SHP-1 Phosphatase Activity
After treatment with SC-43, cell protein extracts were incubated
with anti–SHP-1 antibody in immunoprecipitation buffer [20 mM
Tris-Hcl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1% NP-40, and
1% sodium deoxycholate] overnight. Protein G-Sepharose 4 Fast
Flow (GE Healthcare Bio-Science, NJ) was added to each sample,
followed by incubation for 3 hours at 4°C with rotation. A Rediplate
96 Enzchekr Tyrosine Phosphatase Assay Kit (R-22067) was used for
SHP-1 activity assay (Molecular Probes, Invitrogen, CA). For the
examination of the SHP-1 activity in the SHP-1–containing
immunoprecipitation of cellular extract, 1 mg of whole-cell lysates
was incubated with anti–SHP-1 antibody in immunoprecipitation
buffer overnight. Then, samples were incubated with Protein
G-Sepharose 4 Fast Flow for 3 hours at 4°C with rotation and finally
treated with SC-43 for 2 hours at 4°C. The SHP-1 activity in SHP-1–
containing immunoprecipitation of cellular extract following SC-43
treatment was determined by using a Rediplate 96 Enzchekr Tyrosine
Phosphatase Assay Kit.
Xenograft Tumor Growth
We subcutaneously injected Hct-116 cells (2 × 106) into the
posterior flank of nude mice and then treated them with SC-43 [per
os (p.o.), 10 mg/kg per day], regorafenib (p.o., 10 mg/kg per day), or
vehicle when the tumors became palpable and grew rapidly. The
tumor size of SC-43–, regorafenib-, or vehicle-treated tumors was
measured on days 0, 4, 7, 11, 14, 18, 21, 24, and 25. On day 25 the
tumor weights were measured after tumor excision.
Patient Specimens
Patients with CRC determined according to the World Health
Organization criteria were enrolled from January 2002 through
January 2014 and classified according to the American Joint
Committee on Cancer Staging System (version 6). Clinical data
were obtained from the cancer registry. Overall survival was defined as
the time from primary resection to death from cancer. The follow-up
period ended in January 2014 or at the time of death of the patient.
Left colon cancer was defined as a malignancy in the splenic flexure,
descending colon, sigmoid colon, rectosigmoid colon, and rectum.Immunohistochemistry
For tissue microarray and immunohistochemistry, the procedures
followed our previous methods and the manufacturer’s instructions
[35]. SHP-1 and p-STAT3Tyr705 antibodies were purchased from
Abcam (Cambridge, MA). Omission of the primary antibody served
as a negative control. Immunopositive results were evaluated by 2
pathologists. The intensity of stained cells was scored as 0, 1, 2, or 3.
Percentages of stained cells were counted. A final immunohisto-chemical score (H-score) was calculated by summing the products of
the staining intensities (0-3) and distributions (0%-100%). H-scores
ranged from 0 to 300. An H-score equal to or greater than 150 was
defined as strongly positive for SHP-1 staining; all others were scored
as weakly positive. An H-score greater than 10 was defined as strongly
positive for p-STAT3Tyr705 staining (nuclear staining); all others were
scored as weakly positive.
Statistical And Survival Analysis
Quantitative data were presented as the mean ± standard deviation
(SD) from three independent experiments. The t test was used to
compare age distribution. The correlations between clinicopatholog-
ical variables and immunopositivity were analyzed using the χ2 test or
Fisher’s exact test. Survival was estimated using the Kaplan-Meier
method. A two-sided P value of less than .05 was regarded as
statistically significant. SPSS software (version 16.00; SPSS, Chicago, IL)
was used for all the statistical analyses.
Results
SC-43 Is More Effective than Regorafenib at Inhibiting
Growth and Inducing Apoptosis in Colon Cancer Cell Lines
SC-43 is a derivative of regorafenib (Figure 1A). Here, we
investigated whether SC-43 exerts better anticancer effects than
regorafenib by inhibiting growth and inducing apoptosis in CRC
cells. We observed that SC-43 was more effective than regorafenib,
showing a gradual decrease in growth 2 days after CRC cells (Hct-15,
Hct-116, DLD1, HT-29, and SW480) were treated with dose
escalation of SC-43 or regorafenib (Figure 1B). Meanwhile, we also
found that CRC cells treated with SC-43 showed more increase in cell
population in the sub-G1 phase and more apoptosis than cells treated
with regorafenib in a dose-dependent manner (Figure 1, C and D).
Taken together, these findings suggest that SC-43may bemore effective
than regorafenib as a potential therapeutic drug for CRC treatment.
Loss of p-STAT3Tyr705 Expression Is Associated with
SC-43–Induced Apoptosis
In CRC, STAT3 activation was determined by an elevated level of
p-STAT3Tyr705, which was constitutively expressed due to its
transcriptional activation in cellular proliferative regulation [15].
Next, we examined whether p-STAT3Tyr705 expression is involved in
SC-43–triggered apoptosis. As shown in Figure 2A, dose escalation of
SC-43–treated CRC cells, including Hct-116, DLD1, HT-29, and
Hct-15, showed a significant gradual decrease in the level of
p-STAT3Tyr705and its related survival markers, including cyclin
D1, Mcl-1, and survivin. Meanwhile, cleaved fragments of PARP,
which are markers of apoptosis, were significantly increased 24 hours
after treatment with an escalating dose of SC-43 (Figure 2A).
Therefore, downregulation of p-STAT3Tyr705 expression was
associated with SC-43–triggered apoptosis in CRC cells. In contrast
to cancer cells, SC-43 treatment had little effects on FHC cells
(normal colon epithelial cell) and CCD-18Co cells (normal colon
fibroblast). The extent of SC-43–induced cell apoptosis and
downregulation of p-STAT3Tyr705 and Mcl-1 in FHC and
CCD-18Co cells was significantly lower than Hct-116 (Supple-
mentary Figure 1). Notably, overexpression of STAT3 in Hct-116
cells not only increased the level of p-STAT3Tyr705but also
significantly inhibited apoptosis induced by treatment with 5 μM
SC-43 for 24 hours (Figure 2B, left panels). Importantly, this
observation was also seen in Hct-15 cells (Figure 2B, right panels).
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Figure 1. SC-43, a derivative of regorafenib, induces more potent apoptosis of CRC cells than regorafenib. (A) Chemical structures of
regorafenib and SC-43. (B) MTT assay was performed to measure the cell viability in parental colon cancer cell lines (Hct-15, Hct-116,
DLD1, HT-29, and SW480) 2 days after treatment with regorafenib or SC-43 in a dose-dependent manner. The results are shown as mean ±
SD of three independent experiments, made in triplicate. *P b .05. (C) Sub-G1 analysis was performed in the cells 2 days after treatment
with regorafenib or SC-43 in a dose-dependent manner. The results are shown as mean ± SD of three independent experiments, made in
triplicate. *P b .05. (D) Apoptotic cell death was measured in the cells 24 hours after treatment with dose escalation of regorafenib or SC-43.
The results are shown as mean ± SD of three independent experiments, made in triplicate. *P b .05.
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apoptosis is dependent on STAT3 inactivation.
SC-43-Enhanced SHP-1 Tyrosine Phosphatase Activity Is
Required for p-STAT3Tyr705 Downregulation and
Apoptosis Induced by SC-43
SHP-1 tyrosine phosphatase activity has been reported to have a
critical role in induction of apoptosis in different cancer types by
depleting the level of p-STAT3Tyr705[14,16–18]. Therefore, we
evaluated whether SHP-1 tyrosine phosphatase activity is involved in
downregulation of p-STAT3Tyr705and apoptosis of CRC cells
triggered by SC-43. Our data revealed that SC-43–treated CRC
cells (Hct-116, DLD1, HT-29, and Hct-15) showed a significantincrease in SHP-1 tyrosine phosphatase activity after treatment with
5 μM SC-43 for 24 hours (Figure 3A, upper panels). Notably,
SC-43–enhanced SHP-1 tyrosine phosphatase activity was further
confirmed in SHP-1–containing immunoprecipitation extract incu-
bated with 5 μM SC-43 (Figure 3A, lower panels). Here, we provide
evidence that SC-43 serves as an SHP-1 agonist to increase SHP-1
tyrosine phosphatase activity. To understand whether SC-43–
induced apoptosis via suppression of p-STAT3Tyr705 is dependent
on SHP-1, we used SHP-1 phosphatase-specific inhibitor (PTPIII) to
inhibit SHP-1 activity and observed that SC-43–induced apoptosis
and a decrease of p-STAT3Tyr705were significantly rescued by
treatment with SHP-1 inhibitor (Figure 2B, left panels). Moreover,
siRNA-mediated SHP-1 knockdown also significantly restored the
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Neoplasia Vol. 17, No. 9, 2015 Targeting SHP-1-STAT3 Axis in CRC Fan et al. 691effects of SC-43 on apoptosis and p-STAT3Tyr705expression
(Figure 2B, middle panels). These results demonstrate that SC-43–
induced apoptosis mediated through p-STAT3Tyr705 suppression is
dependent on SHP-1 tyrosine phosphatase activity. On the other
hand, overexpression of SHP-1 reinforced the effects of SC-43 on
apoptosis and p-STAT3Tyr705(Figure 2B, right panels). Taken
together, these results show that SC-43–augmented SHP-1 tyrosine
phosphatase activity is crucial for SC-43–reduced p-STAT3Tyr705
which results in apoptosis in CRC cells.
SC-43 Increases SHP-1 Tyrosine Phosphatase activity By
Directly Impairing the Interaction between N-SH2 and PTP
Catalytic Domains of SHP-1
To further investigate the mechanism through which SC-43
increased SHP-1 tyrosine phosphatase activity, we transfected
Hct-116 cells with wild-type or mutant SHP-1 (dN1 and D61A).
In SHP-1, intramolecular inhibition occurs through association of theN-SH2 domain with the PTP catalytic domain which is stabilized by
a salt bridge between Asp61 (D61) and Lys362 (Figure 3C, upper
panels).The dN1 has a deletion of the N-SH2 domain of SHP-1, the
D61A point mutant mimics the open conformation of SHP-1, and
both serve as constitutive activators (Figure 3C, upper panels).The
dN1 and D61A mutant SHP-1 showed an increase in SHP-1 tyrosine
phosphatase activity (Figure 3C, lower panels) but displayed a marked
decrease in p-STAT3Tyr705level compared with wild-type SHP-1
(Figure 3D, upper panels). Importantly, SC-43 significantly increased
SHP-1 tyrosine phosphatase activity in wild-type SHP-1–transfected
but not in dN1 or D61A mutant SHP-1–transfected Hct-116 cells
(Figure 3C, lower panels). This model provides evidence that SC-43
increases SHP-1 tyrosine phosphatase activity through the direct
disruption of the interaction between the N-SH2 domain and the
PTP catalytic domain of SHP-1 that further relieves the autoinhibi-
tion of SHP-1. In addition, wild-type SHP-1–transfected Hct-116
cells showed a marked decrease in p-STAT3Tyr705level (Figure 3D,
692 Targeting SHP-1-STAT3 Axis in CRC Fan et al. Neoplasia Vol. 17, No. 9, 2015upper panels) and a significant increase in apoptosis (Figure 3D, lower
panels) following SC-43 treatment. However, this observation was not
seen in dN1 or D61A mutant SHP-1–transfected Hct-116 cells
following treatment with SC-43 (Figure 3D). Our model thereforeA
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In Vivo than Regorafenib by Targeting SHP-1–Dependent
STAT3 Inhibition
Next, to investigate whether SC-43 has a better therapeutic effect
on tumorigenesis in vivo than regorafenib, Hct-116 cells (2 ×106)
were subcutaneously injected into the posterior flank of nude mice,
and then SC-43 (p.o.,10 mg/kg per day), regorafenib (p.o.,10 mg/kg
per day), or vehicle was administered when the tumors became
palpable and grew rapidly. As shown in figure 4, A and B, mice
receiving SC-43 or regorafenib treatment exhibited a reduction in
tumor growth and tumor weight compared with vehicle-treated mice.
Importantly, the group receiving SC-43 displayed a more effective
reduction in tumor growth (Figure 4A) and tumor weight (Figure 4B)
than the regorafenib treatment group. Notably, SC-43–treated
tumors showed relatively lower p-STAT3Tyr705level but had
significantly higher SHP-1 tyrosine phosphatase activity
(Figure 4C) compared with regorafenib-treated tumors. The data
above demonstrate that SC-43 is more efficient than regorafenib at
curbing tumorigenesis in vivo by targeting SHP-1–dependent
STAT3 inactivation signaling. Collectively, our data establish
SC-43 as a potent pharmacological SHP-1 agonist that enhances
SHP-1 activation by relieving the inhibitory N-SH2 domain
of SHP-1, leading to STAT3 inactivation and apoptosis in CRC
cells (Figure 4D).
SHP-1 Is Significantly and Negatively Correlated with
p-STAT3Tyr705 Expression in CRC Tissues
We used immunohistochemistry to examine the expression level of
SHP-1 and p-STAT3Tyr705 in CRC tissues and then investigated the
clinical relevance of SHP-1 and p-STAT3Tyr705 and the clinicopath-
ological parameters of CRC patients. Two hundred and forty-three
CRC patients were enrolled for this clinical analysis. As shown in
Table 1, neither SHP-1 nor p-STAT3Tyr705 expression had a
significant correlation with age, gender, location, clinical stage, grade,
or lymphovascular invasion. Moreover, there was no correlation
between SHP-1 expression and pathology. However, a significant
positive correlation was observed between p-STAT3Tyr705expression
and pathology, especially in mucinous adenocarcinoma (MAC) (P =
.036). Importantly, we observed that a significant negative correlation
existed between SHP-1 and p-STAT3Tyr705expression (P = .038)
(Table 1). The total survival curve for the 243CRCpatients is shown in
Figure 5. A Kaplan-Meier analysis showed that patients with strong
SHP-1 andweak p-STAT3Tyr705expression had significantly higherOS
compared with patients with weak SHP-1 and strong p-STAT3Tyr705Figure 3. SC-43 enhances SHP-1 tyrosine phosphatase activity by
p-STAT3Tyr705signaling and further induce apoptosis. (A, upper pane
(Hct-116, DLD1, HT-29, and Hct-15) after treatment with or without 5
tyrosine phosphatase activity in immunoprecipitation-SHP-1–contain
independent experiments,made in triplicate.*P b .05. (B) SC-43 induced
dependent on SHP-1 as assessed by using 20 nM of SHP-1 phosphatas
SHP-1 as shown in the left panels andmiddle panels, respectively. (Rig
SC-43 increased the effects of SC-43 on p-STAT3Tyr705 and apoptos
independent experiments,made in triplicate.*Pb .05. (C,upper panels) A
deletion of theN-terminal inhibitory domain, andD61A, a single pointmu
5 μM SC-43, SHP-1 activity was potently increased in wild-type SHP-1–
Data from SHP-1 activity are shown asmean ± SD of three independen
panels) Western blotting of p-STAT3Tyr705 and SHP-1 in the wild-type a
days after treatment with or without SC-43 at 5 μM. (Lower panels) Ap
Data from apoptosis assay are shown as mean ± SD of three indepenexpression (P = .029) (Figure 5). These observations indicate that
patients with SHP-1–dependent STAT3 inactivation may have OS
benefits and better clinical prognosis and also revealed that SHP-1 and
p-STAT3Tyr705are the relevant therapeutic targets as well as suitable
prognostic markers for CRC treatment.
Discussion
Regorafenib is approved for the treatment of mCRC [2] and is also a
promising treatment for gastrointestinal stromal tumors [19]. It serves
as a multitargeted tyrosine kinase inhibitor of BRAF, VEGFR-1,
VEGFR-2, VEGFR-3, KIT, TIE-2, PDGFR-Β, FGFR-1, RET, and
RAF-1, which are involved in oncogenesis, angiogenesis, and the
maintenance of the tumor microenvironment [20]. In our earlier
study, we reported that SHP-1 is a pharmacological target of
regorafenib in CRC [11]. Regorafenib markedly enhances the
tyrosine phosphatase activity of SHP-1 that negatively targets
p-STAT3Tyr705signaling, resulting in apoptosis in vitro and suppres-
sion of tumorigenesis in vivo[11].Here we demonstrated that SC-43,
a derivative of regorafenib, inhibits Hct-116 xenograft growth by
downregulating p-STAT3Tyr705 level more potently than regorafenib
but inducing a more significant increase in SHP-1 activity, suggesting
that SC-43 has more therapeutic efficiency than regorafenib by
targeting SHP-1–dependent p-STAT3Tyr705inhibition. In addition,
we tested the effects of regorafenib and SC-43 on kinase inhibition.
Regorafenib, but not SC-43, significantly inhibited the activity of
Raf-1 (Supplementary Figure 2), suggesting that the effects of
regorafenib and SC-43 on SHP-1–dependent STAT3 inactivation
were kinase-independent effects. Most importantly, our present
findings demonstrate the mechanism by which SC-43 enhances
SHP-1 activity, which is through direct interaction with the
inhibitory N-SH2 domain and catalytic PTP domain of SHP-1 to
relieve the autoinhibition of SHP-1. The observations were consistent
with the mode of action of regorafenib in enhancing SHP-1
activity [11]. Our study, therefore, not only verified that SHP-1 is
a pharmacological target of SC-43 but also identified SC-43 as a
potent agonist of SHP-1, which negatively regulates p-STAT3Tyr705
signals and consequently induces apoptosis and suppresses xenograft
growth in a preclinical CRC model. On the other hand, sufficient
data from in vivo animal study are still lacking. Therefore, much more
attention should be paid when generating an orthotopic tumor model
in place of a xenograft tumor model that will be a good approach to
further support our in vitro findings.
To our knowledge, this is the first study to report the clinical
relevance of SHP-1 and p-STAT3Tyr705 and the novel relationshiptargeting the autoinhibited SH2 domain of SHP-1 to suppress
ls) SHP-1 tyrosine phosphatase activity was measured in the cells
μMSC-43 for 24 hours. (Lower panels) SC-43 increased the SHP-1
ing cell extract. The results are shown as mean ± SD of three
a decrease in p-STAT3Tyr705. Apoptosis occurring in Hct-15 cells was
e-specific inhibitor (PTPIII) and 25 nM of siRNA specifically depleted
ht panels) Overexpression of SHP-1 in Hct-15 cells treated with 5 μM
is. Data from apoptosis assay are shown as mean ± SD of three
schematic representation ofwild-type andmutant SHP-1 (dN1with a
tation). (Lower panels) Twodays after Hct-116cellswere treatedwith
expressing but not in dN1 or D61A mutant SHP-1–expressing cells.
t experiments, made in triplicate (*P b .05; nonsignificant). (D, upper
nd mutant-type (dN1 And D61A) SHP-1–transfected Hct-116 cells 2
optosis was detected in these cells as shown in upper panels of (D).
dent experiments, made in triplicate (*P b .05; nonsignificant).
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Figure 4. SC-43 shows more effective tumor inhibition than regorafenib in a CRC subcutaneous tumor model. (A) Tumor sizes were
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potent apoptosis inCRCwhichwasmediated throughSC-43–enhancedSHP-1 activity. SC-43 had thepotential to dock to the inhibitoryN-SH2
domain and the catalytic PTP domain of SHP-1, resulting in the direct relief of autoinhibition of SHP-1. The activity Of SHP-1 tyrosine
phosphatase specifically increased the susceptibility to p-STAT3Tyr705, which was the major trigger of apoptosis.
694 Targeting SHP-1-STAT3 Axis in CRC Fan et al. Neoplasia Vol. 17, No. 9, 2015between the SHP-1-STAT3 axis and OS of CRC patients. We
observed that SHP-1 expression was significantly and negatively
correlated with p-STAT3Tyr705 expression in the tissues of 243 CRC
patients. This observation further supported our results that SHP-1 is
a negative regulator of p-STAT3Tyr705 signaling in a preclinical CRC
model. Most importantly, CRC patients with strong SHP-1 and weak
p-STAT3Tyr705 expression had significantly higher OS than patients
with weak SHP-1 and strong p-STAT3Tyr705expression, suggesting
that patients with SHP-1–dependent STAT3 inactivation are likely to
have OS benefit and better clinical outcome. Thus, SHP-1 may serve
as a useful prognostic marker to determine clinical outcome and
may also be a promising pharmacological target for therapeutic
intervention for CRC. Overall, our findings present a basis for
pharmacologically targeting SHP-1–dependent STAT3 inactivation
using SC-43 rather than regorafenib. Use of SC-43 may improve
OS of patients and provide an effective pharmacotherapeutic
option for patients who have exhausted currently approved and
standard therapies.MAC of CRC is an uncommon histological subtype of
adenocarcinoma (approximately 5%-15%) [21] with more than
50% extracellular mucin within the tumor [22]. MAC is one of the
most aggressive phenotypes of stage III CRC [23]. The clinical
outcome of MAC is extremely poor once recurrence occurs [23] and
is usually associated with a modest increase in mortality due to an
increase in mucinous differentiation [24]. Moreover, ample evidence
has demonstrated a strong correlation between mucin expression and
worse prognosis in various other tumor types [23,25–27]. Mucins are
known to participate in cellular growth, differentiation, transforma-
tion, invasion, and metastasis during cancer development [25,28,29].
Most notably, our data specifically showed that patients with MAC
but not other subtypes of CRC had a significant and positive
correlation with p-STAT3Tyr705 expression. Importantly, several
studies have illustrated that STAT3 activation has a key role in mucin
overexpression and cancer development [30–33]. In addition, STAT3
activation has been reported to serve as a marker of poor prognosis in
OS of human CRC [34]. Collectively, our findings reveal a tight
Table 1. The Association between Clinicopathological Parameters and SHP-1 and p-STAT3Tyr705 Expression (N = 243)
Clinicopathological Parameters SHP-1 p-STAT3Tyr705
Weak Strong Weak Strong
n (%) n (%) P n (%) n (%) P
Age (mean/SD) 62.3 ± 13.0 65.6 ± 13.1 63.4 ± 13.6 65.3 ± 12.4
Gender Female 40 47.6 44 52.4 .690 53 63.1 31 36.9 .795
Male 71 44.9 87 55.1 97 61.4 61 38.6
Location Left 57 40.1 85 59.9 .33 90 63.4 52 36.6 .594
Right 54 54.0 46 46.0 60 60.0 40 40.0
Stage I 6 35.3 11 64.7 .309 12 70.6 5 29.4 .864
II 36 53.7 31 46.3 40 59.7 27 40.3
III 29 39.7 44 60.3 46 63.0 27 37.0
IV 40 47.1 45 52.9 52 61.2 33 38.8
Pathology Adenocarcinoma 102 44.2 129 55.8 .097 147 63.6 84 36.4 .036
Carcinoma 1 100.0 0 .0 0 .0 1 100.0
MAC 7 77.8 2 22.2 2 22.2 7 77.8
Signet ring cell 1 100.0 0 .0 1 100.0 0 .0
Primary T4 or not T1-3 60 45.1 73 54.9 .877 87 65.4 46 34.6 .071
T4 31 46.3 36 53.7 35 52.2 32 47.8
Grade Low 95 44.2 120 55.8 .255 130 60.5 85 39.5 .157
High 12 57.1 9 42.9 16 76.2 5 23.8
Lymphovascular invasion Without 80 46.0 94 54.0 .761 110 63.2 64 36.8 .955
With 24 43.6 31 56.4 35 63.6 20 36.4
p-STAT3Tyr705 Weak 61 40.7 89 59.3 .038 150 100.0 0 .0 –
Strong 50 54.3 42 45.7 0 .0 92 100.0
SHP-1 Weak 111 100.0 0 .0 – 61 55.0 50 45.0 .038
Strong 0 .0 131 100.0 89 67.9 42 32.1
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MAC of CRC and further support the assertion that p-STAT3Tyr705
may be a relevant therapeutic target for the treatment of MAC of
CRC. Although the mechanism through which p-STAT3Tyr705
signaling increases mucinous differentiation in MAC is still poorly
understood in our present study, we provide a new drug, SC-43, that
is not only a potent SHP-1 agonist but also a STAT3 inhibitor. We
suggest that pharmacologically targeting p-STAT3Tyr705 by SC-43–
enhanced SHP-1 activity may improve OS and result in better clinical
outcome and will be an effective pharmacotherapy for MAC of CRC.
In conclusion, we investigated the clinical relevance of SHP-1 and
p-STAT3Tyr705 in CRC and demonstrated a tight relationship
between the SHP-1-STAT3 axis and OS of CRC patients, indicating
that SHP-1 is not only a useful prognostic marker but also a good
pharmacological target for CRC therapy. Importantly, we discovered(3) vs (1) p=0.029 95%CI 1.053-2.649
(3) vs (2) p=0.080 95% CI 0.957-2.156
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Figure 5. Overall survival of patients with CRC relative to the
expression of SHP-1 and p-STAT3Tyr705. Patients with strong
SHP-1and weak p-STAT3 expression had better OS than others.that SC-43 is a potent therapeutic agonist of SHP-1 that exerts more effective
anti-CRC effects than regorafenib by inhibiting p-STAT3Tyr705signals.
Therefore, targeting SHP-1-STAT3 signaling by SC-43 may be an
alternative pharmacotherapy for the treatment of CRC.
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